UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The rate of viral rebound after attainment of an HIV load < 50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study

Smith, CJ; Phillips, AN; Hill, T; Fisher, M; Gazzard, B; Porter, K; Gilson, R; ... United Kingdom HIV Cohort Study, ; + view all (2005) The rate of viral rebound after attainment of an HIV load < 50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study. JOURNAL OF INFECTIOUS DISEASES , 192 (8) 1387 - 1397. Green open access

[img]
Preview
PDF
6645.pdf

Download (123kB)

Abstract

Background. Relatively few data are available on the association between the use of specific antiretroviral drugs and the rate of viral rebound in those attaining a viral load (VL) < 50 copies/mL while receiving highly active antiretroviral therapy ( HAART).Methods. Patients achieving a VL < 50 copies/mL for the first time while receiving HAART were followed until viral rebound (2 consecutive VLs > 500 copies/ mL). Pre-HAART antiretroviral-naive patients were analyzed separately from those with nucleoside reverse transcriptase inhibitor (NRTI) experience.Results. Of 3565 suppressed antiretroviral-naive patients, 381 experienced viral rebound ( rate, 6.26 events/100 person-years of follow-up [pyrs][ 95% confidence interval {CI}, 5.63-6.89 events/ 100 pyrs]). For those receiving efavirenz, the rate was 4.08 ( 95% CI, 3.16-5.01) events/ pyrs. Compared with this, the rebound rate for those receiving indinavir was 1.52 times higher ( rate ratio [ RR], 1.52 [ 95% CI, 0.82-2.84]). RRs ( 95% CIs) for other drugs were: soft-gel saquinavir, 0.54 ( 0.07-3.97); nelfinavir, 2.44 ( 1.68-3.54); indinavir/ritonavir, 1.96 ( 1.02-3.77); saquinavir/ritonavir, 1.12 ( 0.48-2.61); lopinavir/ritonavir, 1.23 ( 0.58-2.59); nevirapine, 1.53 ( 1.11-2.10); and abacavir, 2.03 ( 1.26-3.25). Of 810 NRTI-exposed patients, 145 experienced viral rebound ( rate, 8.29 [ 95% CI, 6.94-9.64] events/ pyrs). For those receiving efavirenz, the rate was 5.25 ( 95% CI, 3.11-8.30) events/ pyrs. Compared with this, the RRs ( 95% CIs) were: indinavir, 1.75 ( 0.82-3.73); hard-gel saquinavir, 3.48 ( 0.36-33.37); nelfinavir, 2.64 ( 1.37-5.08); indinavir/ritonavir, 0.32 ( 0.04-2.49); saquinavir/ritonavir, 0.64 ( 0.23-1.80); nevirapine, 1.65 ( 0.90-3.02); and abacavir, 1.82 ( 0.73-4.52).Conclusions. We must make comparisons of antiretroviral outcomes in observational data with caution; however, our results suggest that, in those with VLs < 50 copies/ mL, certain drugs may be associated with higher rebound rates than others.

Type: Article
Title: The rate of viral rebound after attainment of an HIV load < 50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study
Location: Boston, MA
Open access status: An open access version is available from UCL Discovery
Keywords: IMMUNODEFICIENCY-VIRUS-INFECTION, INHIBITOR-CONTAINING REGIMENS, PROTEASE INHIBITOR, HIV-1-INFECTED PATIENTS, EXPERIENCED PATIENTS, VIROLOGICAL FAILURE, THERAPY, NEVIRAPINE, EFAVIRENZ, SUPPRESSION
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/6645
Downloads since deposit
381Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item